Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

GlobeNewswire April 15, 2024

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire April 10, 2024

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

GlobeNewswire April 1, 2024

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

GlobeNewswire March 25, 2024

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

GlobeNewswire March 25, 2024

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

GlobeNewswire March 19, 2024

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

GlobeNewswire March 5, 2024

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

GlobeNewswire February 27, 2024

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire February 20, 2024

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

GlobeNewswire January 23, 2024

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

GlobeNewswire January 4, 2024

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

GlobeNewswire December 11, 2023

AXSM FINAL DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Shareholders to Contact the Firm Today

Newsfile December 7, 2023

FINAL AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 7, 2023

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

GlobeNewswire December 7, 2023

AXSM DEADLINE ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Shareholders to Contact the Firm Today

Newsfile December 6, 2023

FINAL AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 6, 2023

AXSM DEADLINE ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors of Class Action Lawsuit - Contact the Firm Today

Newsfile December 5, 2023

FINAL AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 5, 2023

UPCOMING AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 4, 2023